Last reviewed · How we verify
valsartan, fluvastatin
This combination reduces blood pressure by blocking angiotensin II receptors (valsartan) and lowers cholesterol by inhibiting HMG-CoA reductase (fluvastatin).
This combination reduces blood pressure by blocking angiotensin II receptors (valsartan) and lowers cholesterol by inhibiting HMG-CoA reductase (fluvastatin). Used for Hypertension with hypercholesterolemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
At a glance
| Generic name | valsartan, fluvastatin |
|---|---|
| Sponsor | Novartis |
| Drug class | ARB/statin combination |
| Target | Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, thereby lowering blood pressure. Fluvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and cardiovascular risk. Together, they address two major cardiovascular risk factors in a single formulation.
Approved indications
- Hypertension with hypercholesterolemia
- Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Common side effects
- Dizziness
- Fatigue
- Headache
- Muscle pain (myalgia)
- Elevated liver enzymes
- Hyperkalemia
Key clinical trials
- Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome (PHASE2)
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination (NA)
- Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan (NA)
- Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome (PHASE4)
- Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction (PHASE4)
- Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valsartan, fluvastatin CI brief — competitive landscape report
- valsartan, fluvastatin updates RSS · CI watch RSS
- Novartis portfolio CI